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I. Abstract 
 
Heart disease is the leading cause of  death for both men and women worldwide1. With this 
project, we propose a new therapy to provide a safer and more effective thrombolytic for patients 
who suffer an MI. von Willebrand Factor (VWF) is a known mediator in platelet adhesion and 
aggregation. We have developed  an RNA aptamer which acts to directly inhibit von Willebrand 
Factor. This aptamer, named DTRI-031, can be reversed with an antidote oligonucleotide, DTRI-
025, that was specifically developed to rapidly and durably reverse DTRI-031 function. Previous 
studies in this laboratory have demonstrated that DTRI-031 resulted in decreased infarct sizes 
after stroke and decreased platelet reactivity after vascular injury in canines. Our current study 
will first attempt to modify a large animal model of porcine myocardial infarction (MI) for canine 
utilization. Once our canine MI model is characterized, we will attempt to demonstrate the ability 
of DTRI-031 to maintain cardiac function and platelet reactivity after MI compared to vehicle 
control. We will utilize cardiac magnetic resonance imaging (MRI) to measure ejection volume, 
stroke volume, and cardiac output. We will stain hearts with Evan’s Blue after MI to compare 
infarct size. Lastly, we will monitor platelet reactivity utilizing whole blood aggregometry before 
MI, during ischemia, and at time of sacrifice in addition to measurement of plasma VWF levels. 
Heart rate, body temperature, and blood pressure monitoring ensure physiological conditions are 
maintained throughout the surgical procedures. We anticipate that the canine MI model will be 
characterized rapidly with little modification from the previously published porcine model and 
that DTRI-031 will result in less infarction and retain greater cardiac function. This is an ongoing 
experiment.  
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II. INTRODUCTION 
A. Historical Background  
According to the Centers for Disease Control and Prevention, the leading cause of death of 
men and women is heart disease. In the United States, almost every 1 in 3 deaths each year is from 
cardiovascular disease, with a heart attack occurring every 40 seconds1. Heart attack, or acute 
myocardial infarction (AMI) can occur when a blood vessel in the heart is blocked and muscle is 
damaged due to lack of oxygen2. According to the National Institutes of Health’s (NIH) National 
Heart, Lung and Blood Institute, there are treatments available for suspected heart attacks which 
include: aspirin and nitroglycerin. These treatments are used in order to prevent thrombosis or 
relax blood vessels, respectively to maintain blood flow. If MI does occur, thrombolytics, 
anticoagulants and other non-surgical interventions are used. Reperfusion therapies decrease the 
morbidity rate of AMI3. Unfortunately, Sánchez-Hernádez et al describe studies that have shown 
how blood flow restoration results in an inflammatory response which can further the damage4.  In 
summary, there is an immediate need for treatments which utilize novel targets to reduce infarct 
size and preserve cardiac function.  
 
B. Hemostasis  
Understanding blood hemostasis and how a blood clot forms is important to understand MI 
and MI treatment strategies. Complications from platelet hyperactivity in the first stages of an AMI 
are common and related to platelet aggregation, ultimately resulting in thrombosis5.   
Subendothelial components are exposed at sites of injury in vasculature. These components are a 
key factor in aggregation6. Tomaiuolo et al illustrates a model of the hemostatic response to an 
injury in the vasculature 7. The platelet plug formation requires a cascade of events of platelet 
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aggregation and activation. Interactions and adhesion factors initiate the aggregation, followed by 
platelet activation at that site and stabilization of the activated platelets in a core region. The 
adhesion of platelets to the injury sites can lead to excessive accumulation and result in thrombus 
formation which may lead to AMI. Many factors are involved in this process. Studies have shown 
that von Willebrand Factor (VWF) plays a role in platelet aggregation and thrombus formation6,7,8 
(Figure 1). 
 
C. von Willebrand Factor  
VWF has recently become an important factor in clot formation. VWF is a glycoprotein 
and each subunit has multiple binding sites, including binding sites for platelet glycoprotein Ib 
(GPIb) and GPIIb/IIIa9 (Figure 2). GPIb is a receptor found on the surface of platelets and it 
functions as a meditator for the first step in platelet adhesion. It facilitates the binding of VWF 
under injury conditions31,32. GPIIb/IIIa is an integrin found on platelets. It has a receptor for VWF 
and aids in the activation of platelets33,34. VWF is produced by endothelial cells and 
megakaryocytes and are stored in Weibel Palade bodies within the endothelium and platelet a-
granules, respectively. They are  released upon injury to the vessel in cases like hypoxia or during 
endovascular procedures such as angioplasty and thrombectomy8,10.  During injury, VWF interacts 
with platelets through the GPIb-IX-V receptor and GPIIb-IIIa receptor6. GPIba binds to VWF at 
the A1 domain which is exposed during high arterial shear rates such as atherosclerosis and MI. 
This binding is not found in static conditions.  This binding by the GPIb-IX-V complex plays a 
major role in aggregation6,8,11. von Willebrand Disease (VWD) is characterized by a reduction in 
VWF in blood plasma. The predominant form of VWD, called Type 1 VWD, presents itself with 
uncommon and increased bleeding during dental procedures and menorrhagia in women12. Patients 
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with VWD have been shown to be more protected from cardiovascular and cerebrovascular 
events13. Following AMI, acute ischemic stroke (AIS) and cardioembolic stroke, patients have 
increased levels of plasma VWF13-18.  
VWF also plays a significant role in inflammation as it relates to thrombosis. A study done 
by Andreotti et al demonstrates the rapid changes in plasma following tissue damage and states 
that VWF levels were higher in the first 48 hours after infarction compared to the concentrations 
after 90 days19. There is a high rate of platelet adhesion to the subendothelium following ischemia 
reperfusion (I/R) at the injury site due to the excess exposed VWF which can increase myocardial 
infarct size. The inflammatory response is enhanced and can lead to a higher tendency for vessels 
to re-occlude in the same area.20 Until recently, VWF has been overlooked as a suitable target for 
therapeutics13 and the inhibition of VWF could show potential. With that, Dr. Nimjee’s group has 
isolated an RNA aptamer, DTRI-031, to inhibit VWF10 by binding to the A1 domain of VWF 
(Figure 2). 
D. DTRI-031 
Aptamers are DNA or RNA ligands that act as inhibitors that bind to and inhibit a target protein 
with high affinity and specificity. Aptamers are created by SELEX, (Systematic Evolution of 
Ligands by EXponential enrichment), an in-vitro selection technique developed by Tuerk and Gold, 
and Ellington and Szostak13,21,22 (Figure 3). There are many advantages of using aptamers 
including the ability to modify their half-life, unlimited shelf life and low to no immunogenicity. 
Also, they can be isolated to any protein and have high specificity towards that target23.  A matched 
antidote, DTRI-025, was also created using the properties of Watson-Crick base-pairing (Figure 
4). DTRI-025 binds and inhibits DTRI-031 which is imperative as with any drug that prevents or 
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treats thrombosis, such as treatments for AMI and AIS that have a risk of hemorrhage caused by 
current thrombolytic drugs10. 
E. Project Overview 
We previously tested the efficacy of DTRI-031 in preventing an occlusive thrombus12. 
More recently, we have demonstrated that DTRI-031 can recanalize a formed clot better than rTPA, 
the only approved thrombolytic drug. The same model was also utilized to study the efficacy of 
DTRI-031 to thrombolyse stabilized blood clots in both mice and canines12,30 . In both of these 
small and large animal models of vascular injury, VWF inhibition by DTRI-031 resulted in greater 
thrombolysis. 
My project will determine whether DTRI-031 efficacy translates into myocardial infarction, 
another disorder caused by thrombosis. I will first attempt to translate a previously performed MI 
model from porcine to canine then evaluate the effect of DTRI-031 on the preservation of cardiac 
function after MI. Animals will be subjected to 60 minutes of ischemia induced by balloon 
insertion and inflation in the LAD followed by reperfusion and infusion with either 0.5mg/kg 
DTRI-031 (5 minute bolus) or vehicle for an additional 60 minutes. Whole blood will be drawn 
for platelet aggregometry (Chronolog) and VWF quantitation at designated times and as well as 
digital subtraction angiography performed to monitor cardiac perfusion. To evaluate infarction 
size and cardiac function, cardiac MRI will be performed 120 minutes after treatment infusion and 
Evans Blue staining will be performed at the time of sacrifice to verify infarct size. We anticipate 
that DTRI-031 will result in a smaller infarct size and will retain greater cardiac function. 
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III. Materials and Methods 
Animal procedures were approved by The Ohio State University Institutional Animal Care 
and Use Committee (IACUC). Five adult canines (<1year old) were obtained from Covance and 
housed in a temperature and humidity-controlled vivarium in Wiseman Hall with free access to 
food and water (Table 1). 
In vivo myocardial injury: Canine AMI were performed as previously published21.  A model of 
myocardial ischemic reperfusion (IR) infarction using a simple catheterization procedure to 
occlude the mid left anterior descending artery (LAD) was used.   Adult beagles, both male and 
female, 8-12kg were fasted overnight with free access to water before MI. A pre-anesthetic 
intramuscular administration of acepromazine (0.2 mg/kg) was delivered and a 20 gauge catheter 
was introduced into a cephalic vein. Anesthesia was induced with intravenous administration of 
ketamine (10 mg/kg) and midazolam (0.025 mg/kg).  Following induction, dogs were intubated 
and mechanically ventilated using constant inhaled isoflurane for anesthesia maintenance.  The 
dogs were positioned supine and an arteriotomy was performed to expose either the right femoral 
or left carotid artery. A 7F arterial sheath was introduced into the isolated vessel for access and 
invasive blood pressure measurements.  To assess baseline hemodynamics, a 6F pig-tail catheter 
was placed into the sheath and advanced via a .035” guide wire into the left ventricle. As an 
antiarrhythmic, an intravenous bolus of amiodarone (30 mg) and lidocaine (20 mg) was 
administered prior to angiograms. The pig-tail catheter was removed and replaced with a 6F IM 
or RCB guiding catheter (Cordis, Miami Lakes, FL) which was advanced to the left main 
coronary ostium. Digital angiography was obtained of the target vessel prior to the initiation of 
ischemia. A 2.5 mm x 15 mm coronary angioplasty balloon catheter (Boston Scientific, Natick, 
MA) was positioned in the mid-LAD. The balloon was inflated to nominal pressure preventing 
 9 
blood flow to the distal coronary to induce ischemia.  Total occlusion of the coronary artery 
distal to the balloon was verified by angiogram. EKG and blood pressure were closely monitored 
during the ischemic period. Episodes of ventricular fibrillation were cardioverted using 
nonsynchronized direct current defibrillation set at 200J.  After 60 minutes of ischemia, the 
balloon was deflated and removed from the vessel. A follow up angiogram was performed to 
verify restoration of blood flow in the previously occluded artery.  Thrombolytic therapy was 
then initiated. 
 
Angiography:  Canine digital subtraction angiography (DSA) was performed as previously 
published21. Coronary angiography of the target vessel was conducted with a 7-Fr guide catheter 
(AL1 STSH Guide, Boston Scientific, Natick, MA) advanced into the left main coronary ostium. 
A coronary angioplasty balloon, catheter sized (Sprinter OTW 4.0x10 mm balloon, Medtronic Inc., 
Minneapolis, MN) according to the target vessel, was positioned in the left anterior descending 
artery (LAD) proximal to the first diagonal artery branch. To induce ischemia, the balloon was 
inflated to nominal pressure and cessation of blood flow to the distal LAD was confirmed with 
DSA. Episodes of ventricular fibrillation were cardioverted using nonsynchronized direct current 
defibrillation set at 360J. After 60 minutes of ischemia the balloon was deflated, removed from 
the vessel, and restoration of flow verified with an angiogram.  The animals were monitored for 
an additional 3 hours and a concluding hemodynamic assessment, left ventriculogram, and 
coronary angiogram were recorded21.  
Infarct Size Assessment: Determination of cardiac infarct size was performed as previously 
published21. Briefly, after MRI and immediately before sacrifice, the angioplasty balloon was re-
inflated into the same position in the LAD. The heart was exposed by a median sternotomy and 
 10 
the LAD was ligated at the proximal end of the inflated angioplasty balloon. The heart was excised 
and perfused with 40-60 ml of 10% Evan’s Blue injected directly into the left and right coronary 
artery ostia for delineation of the area-at-risk (AAR) for myocardial infarction from the non-
ischemic zone. The area of the myocardium that did not stain with Evan’s Blue was defined as the 
AAR21. 
Chronolog and VWF Activity:  Canine whole blood was collected per experimental time points at 
baseline before MI, immediately after ischemia (Baseline 2), 5 minutes, 15 minutes, 30 minutes, 
60 minutes, 90 and 120 minutes after treatment infusion. Whole blood was also collected at time 
of sacrifice. Whole blood was collected for anti-coagulation in sodium citrate tubes for VWF levels 
and lithium heparin tubes for whole blood aggregometry (WBA). Blood for WBA was diluted with 
sterile saline in a 1:1 ratio and rested for 30 minutes in an incubator at 37 degrees Celsius. Platelet 
impedance with collagen, ADP, and botrocetin was measured for 6 minutes using a Chronolog 
platelet aggregometer.  
Imaging: Magnetic Resonance Imaging (MRI) was performed as previously published in the Large 
Animal Catherization Core at baseline and immediately before sacrifice,23. The infarct size in the 
dogs was imaged as previously published13,21,22.  
IV. Results 
As previously discussed, our first goal was to characterize canine MI based on the porcine 
model. The vehicle treatment group thus far has consisted of 5 adult dogs. We successfully 
completed baseline MRI on four of the five dogs prior to the day of the MI procedure. Of the five 
animals on which we initiated the MI protocol, one canine survived throughout MI and MRI to 
experimental time of sacrifice. Experimental protocol consisted of 60 minutes of ischemia, 
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followed by vehicle infusion, 120 minutes of monitoring, MRI and sacrifice for tissue harvest21. 
Dog #M1, CIJCKG died after baseline. CIJCKG experienced complications with placing the 
balloon in the LAD. Dog #M2, CIICPE received 60 minutes ischemia, vehicle infusion, and 
completed 120 minutes of monitoring but died 46 minutes into MRI scanning. Dog #F1, CIICTJ 
died after baseline data collection at the beginning of the MI protocol probably due to anatomical 
abnormalities identified during the baseline MRI. Dog #F2, CIICTL, completed the MI protocol 
(Figure 5). 
Functional Differences:  
To demonstrate the translation of the porcine MI procedure to canines, functional 
differences of ejection volume, cardiac output and stroke volume were evaluated pre-MI and post-
MI (p<0.05). Ejection fraction (EF) is the measurement of how much blood (% of total blood) the 
left ventricle pumps out in one contraction25. The ejection fraction of pre-MI  (52.375%+/-
13.093%, n=4) and of post-MI (32.880%, n=1) were measured (Figure 6). Cardiac output (CO) is 
the total amount of blood that the heart pumps out in one minute27.  The cardiac output of pre-MI  
(18.613+/-11.616 L/min, n=4) and of  post-MI (19.830 L/min, n=1) were measured (Figure 7). 
Stroke volume (SV) is the amount of blood that is ejected from the left ventricle in a heart beat27. 
The stroke volume of pre-MI  (15.755+/-4.139 mL, n=4) and of post-MI (6.080 mL, n=1) were 
measured (Figure 8). 
Infarct Size:  
 To demonstrate the efficacy of DTRI-031 the infarct size was visually assessed21. As stated 
previously, after organ harvest, the heart was removed and perfused with 40-60mL of 10% Evan’s 
Blue (Sigma Aldrich, St Louis, MO). The area that did not stain blue was defined as the Area-at-
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Risk (AAR). We performed infarct assessment on Dog #F2 CIICTL (Figure 9). The infarct size 
of the heart has not quantitatively measured.  
Physiological Effects:  
 Heart rate (HR) and blood pressure (BP) were monitored throughout the experiment and 
reported at baseline before MI, immediately after ischemia (Baseline 2), 5 minutes, 15 minutes, 30 
minutes, 60 minutes, 90 and 120 minutes after treatment infusion and then immediately before 
sacrifice. Normal physiological conditions were maintained throughout those time points. 
Statistical analysis of the data collected was done using a one-way ANOVA for comparison across 
all time points. Baseline heart rate between animals was not significant (n=5, p=0.1341) (Figure 
10). Baseline mean blood pressure  between animals was not significant (n=5, p=0.7253) (Figure 
11). Baseline systolic blood pressure (n=5, p=0.3334) and diastolic blood pressure (n=5, p=0.8498) 
between animals was not significant (Figure 12). 
Platelet Reactivity: 
Platelet reactivity was recorded. Aggregation impedance with collagen, ADP, and 
botrocetin was measured for 6 minutes using a Chronolog whole blood aggregometer. Collagen 
polymerizes into fibrils for platelet activation28. The concentration of collagen used was 3.2μg/ μL. 
Statistical analysis per treatment group was done using a one-way ANOVA for comparison across 
all time points for each parameter: amplitude (ohms), slope (ohms per minute), area under the 
curve (AUC, ohms*time, in % of impedance) and lag time (minutes). The resulting amplitude in 
response to collagen showed no significance (n=3, p=0.6349). The resulting slope in response to 
collagen showed no significance (n=3, p=0.4441). The resulting AUC in response to collagen 
showed no significance (n=3, p=0.7534). The resulting lag time in response to collagen showed 
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no significance (n=3, p=0.0758) (Figure 13). Adenosine diphosphate, ADP, exposes the 
fibrinogen-binding site28.  The ADP concentration used was 20μM. The resulting amplitude in 
response to ADP showed no significance (n=3, p=0.0007). The resulting slope in response to ADP 
showed no significance (n=3, p=0.7637). The resulting AUC in response to ADP showed no 
significance (n=3, p=0.0001). The resulting lag time in response to ADP showed no significance 
(n=3, p=0.3098) (Figure 14). Botrocetin contains a sequence analogous to GPIb  which means it 
can be used to indirectly measure VWF activity. The botrocetin concentration used was 1 μg/ μL. 
The resulting amplitude in response to botrocetin showed no significance (n=3, p=0.0948). The 
resulting slope in response to botrocetin showed significance (n=3, p=0.0472). The resulting AUC 
in response to botrocetin showed no significance (n=3, p=0.4139). The resulting lag time in 
response to botrocetin showed no significance (n=3, p=0.8635) (Figure 15).  
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V. Discussion  
Functional Differences: 
We found there was no significance between animals at baseline in any functional 
parameter. Thus far in these experiments, the pre-MI data and mean +/- standard deviation were 
collected from 4 canines, while the post-MI data resulted from only one canine at time of sacrifice. 
We believe we have translated the previous published porcine model to the canine and have 
adequately characterized the canine model by MRI optimization to be utilized for DTRI-031 
efficacy studies. In the future, we hope to increase this sample size in the negative control group. 
Unfortunately due to the time restrictions we were unable to begin DTRI-031 treated canines to 
determine functional differences and therefore unable to analyze and determine the efficacy of 
DTRI-031 compared to the negative control. With that, we anticipate not only a significance in 
pre- and post-MI differences with DTRI-031 treatment in maintaining cardiac function, but a 
significant preservation compared to the negative control. 
 
Infarct Size:  
The infarct size from one canine was visually assessed from the negative control group. 
Unfortunately we do not yet have DTRI-031 treated hearts for comparison and therefore are unable 
to analyze and determine the efficacy of DTRI-031 against the negative control. For the future of 
this study we plan to complete the negative control group as well as compare with DTRI-031 
treatment. When both the negative control and DTRI-031 hearts have been sectioned and stained, 
the same investigator blinded to treatment will trace and analyze all hearts for consistency and 
accuracy. With that, we anticipate a significantly smaller infarct size with DTRI-031 treatment 
consistent with maintenance of cardiac function compared to the negative control. 
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Physiological Effects: 
 Analysis of heart rate and blood pressure in the animal data thus far suggests that normal 
physiological conditions were maintained throughout the experiment for the negative control 
group (n=5). Unfortunately we do not yet have physiological data from DTRI-031 treated canines 
for comparison and therefore are unable to analyze and determine if there is a difference compared 
to the negative control. For the future of this study we plan to increase the sample size of the 
negative control as well as compare with DTRI-031 treatment. With that, we anticipate no 
significant difference in physiological data with DTRI-031 treatment consistent with our previous 
experiments in other canine models where we have administered DTRI-031 intravenously 
compared to the negative control. 
 
Platelet Activity 
 The platelet reactivity resulting from agonist addition including collagen, ADP and 
botrocetin were recorded for the negative control group only thus far. Chronolog whole blood 
aggregometry was used to determine the impedance of the clot formation. As stated previously, 
statistical analysis for the negative control was done using a one-way ANOVA for comparison 
across all time points for each parameter including amplitude (ohms), slope (ohms per minute), 
area under curve (AUC, ohms*time, in % of impedance) and lag time (minutes). One-way 
ANOVA was used due to the small sample size and the inability to run t-tests with specific time 
points. There was no noted difference across all agonists and each parameter except for the slope 
when using botrocetin. Botrocetin is used for the detection of VWF, which is of major importance 
to this study specifically due to DTRI-031 inhibition of VWF. This is likely due to the increased 
levels of VWF present in blood plasma after an ischemic injury8,10. In the future, we plan to 
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increase this sample size in the negative control. Unfortunately due to the time restrictions we were 
unable to begin DTRI-031 treated canines to determine differences in platelet reactivity and 
therefore unable to analyze and determine the efficacy of DTRI-031 compared to the negative 
control platelet activation and aggregation. With that, we anticipate a significant difference in 
platelet reactivity induced by botrocetin addition with DTRI-031 treatment consistent with our 
previous experiments in other canine models where we have administered DTRI-031 intravenously 
compared to vehicle treatment. Specifically, we believe we will see DTRI-031 blunt or entirely 
eliminate platelet activation and aggregation immediately after infusion begins. 
 
Our canine MI research is expected to continue in hopes to gather more data to accurately 
assess whether DTRI-031 can translate from a stroke to an MI therapeutic. We plan to further our 
collection of the data above by completing the negative control group. We also plan to being using 
DTRI-031 treated animals and compare DTRI-031 to the negative control. In the future, we plan 
to complete ELISAs, Enzyme Linked Immunosorbent Assays, to measure concentrations of VWF 
and ADAMTS13 as it is important for VWF size regulation, and inhibition of VWF by DTRI-031 
should increase this concentration29. 
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VI. Figures:  
Figure 1 
 
 
 
 
 
Figure 1: Role of VWF in platelet aggregation and thrombus formation (Nimjee et al. 2020) 
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Figure 2 
 
 
 
 
Figure 2: The structure of von Willebrand Factor, VWF. The A1 domain is where the aptamer DTRI-031 binds which is the GPIb 
binding site. (Nimjee et al 2020) 
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Figure 3  
 
 
 
 
Figure 3: SELEX Method 
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Figure 4 
 
 
 
 
Figure 4: Inactivation of aptamer DRTI-031 by reverse oligonucleotide antidote DTRI-025 (Nimjee et al. 2020) 
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Table 1 
Sex 
Vehicle 
(5 min bolus, then 40 min infusion) 
Male 0/3 
Female 1/2 
Total 1/5 
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Figure 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CIICPE (M2) 
DOS: 7/26/19 
vehicle 60 min 120 min Monitoring 
vehicle 60 min 120 min Monitoring 
CIICTL (F2) 
DOS 8/2/19 
vehicle 60 min 120 min Monitoring 
CIICTJ (F1) 
DOS 7/30/19 
vehicle 60 min 120 min Monitoring 
CIJCKG (M1) 
DOS 7/23/19 
vehicle 60 min 120 min Monitoring 
CJECTF (M3) 
DOS 1/14/20 
= Baseline angiogram and balloon preparation = MRI 
= Tissue Harvest  
3h after occlusion 
= IV administration 
= Balloon inflation 
= Balloon removal 
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Figure 6 
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Figure 7 
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Figure 8  
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Figure 9 
 
Figure 9:  Dog #F2: CIICTL / Vehicle 
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Figure 10 
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Figure 11 
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Figure 12 
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Figure 13 
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Figure 14 
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Figure 15 
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